Mi SciELO
Servicios personalizadosServicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Enviar articulo por emailIndicadores
Citado por SciELO
Links relacionados
Similares en
SciELO
Compartir
Permalink
Revista de Ciencias Médicas de Pinar del Río
versión On-line ISSN 1561-3194
Resumen
RODRIGUEZ GUTIERREZ, Damary; CERVANTES PELAEZ, Dayan y ROJAS PELAEZ, Yosvany. Infliximab as a therapeutic alternative in perianal fistulizing Crohn's disease. Rev Ciencias Médicas [online]. 2020, vol.24, n.4, e4420. Epub 01-Jul-2020. ISSN 1561-3194.
Introduction:
Infliximab is a drug, a monoclonal antibody with a potent anti-inflammatory action. Its mechanism of action decreases the effect of tumor necrosis factor, on the other hand, it induces apoptosis (cell death) of abnormally activated lymphocytes. It is one of the so-called biological treatments, developed for the treatment of various diseases, including Crohn's disease which is characterized by segmental granulomatous inflammation of the intestinal tract and usually affects the skin tissues.
Case report:
42-year-old white race male with a history of treatment since 2006, he underwent different treatments with few results. A new therapeutic behavior is taken in 2018 with the monoclonal antibody Infliximab.
Conclusions:
results with the new therapy were satisfactory.
Palabras clave : CROHN DISEASE; INFLIXIMAB; RECTAL FISTULA; INFLAMMATORY BOWEL DISEASES; BIOLOGICAL TREATMENT.
